Get the Stockscreener App
758.56
0.71%
3.88
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corp stock is traded at $758.56, with a volume of 516.95K.
It is up +0.71% in the last 24 hours and down -9.76% over the past month.
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$754.68
Open:
$752.57
24h Volume:
516.95K
Relative Volume:
0.59
Market Cap:
$91.17B
Revenue:
$403.43B
Net Income/Loss:
$5.10B
P/E Ratio:
19.72
EPS:
38.4657
Net Cash Flow:
$5.41B
1W Performance:
+1.72%
1M Performance:
-9.76%
6M Performance:
-12.24%
1Y Performance:
+5.75%
1-Day Range:
$748.97
$763.37
1-Week Range:
$748.97
$782.48
52-Week Range:
$637.00
$999.00
Mckesson Corp Stock (MCK) Company Profile
Name
Mckesson Corp
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK vs COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corp
|
758.50 | 90.72B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
263.48 | 51.51B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
200.00 | 46.66B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
73.31 | 8.34B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
1.54 | 1.37B | 14.85M | -136.07M | 7.25M | -0.4726 |
Mckesson Corp Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corp Stock (MCK) Latest News
$663.3 Bn Revenue Cycle Management Market Trends and Global Forecasts Report 2026-2035 - GlobeNewswire Inc.
What Makes McKesson Corporation (MCK) an Attractive Bet? - Insider Monkey
McKesson Corp. stock outperforms competitors despite losses on the day - MarketWatch
McKesson Corp. stock outperforms competitors on strong trading day - MarketWatch
McKesson Corporation (MCK) Highlights Resilience as Its Core Drug Distribution Network Stands the Test of Time - Yahoo! Finance Canada
McKesson Corporation (MCK) Surged 50% on Strong Earnings Growth and Resilient Drug Distribution Model - Yahoo Finance
Government Contract Update: $36M payment to MCKESSON CORPORATION - Quiver Quantitative
5 Insightful Analyst Questions From McKesson’s Q1 Earnings Call - Yahoo Finance
McKesson Settles Trade Secrets Suit Against Former Exec - Law360
McKesson moves MMS closer to IPO - HME News
MCK Stock Price, Quote & Chart | MCKESSON CORP (NYSE:MCK) - ChartMill
AQR Alternative Risk Premia Fund's McKesson Corp(MCK) Holding History - GuruFocus
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know - Yahoo! Finance Canada
How The Evolving Story On McKesson (MCK) Is Shaping Its Valuation Outlook - Yahoo Finance
UBS Says McKesson’s (MCK) FY27 Outlook Looks “Good Enough” After Q4 - Insider Monkey
McKesson Corp. stock underperforms Monday when compared to competitors - MarketWatch
McKesson Q4 Earnings Call Highlights - sharewise.com
McKesson Says Loper Bright Sinks IRS Cost-Sharing Rules - Law360
McKesson says it is well-positioned going into 2027 - HME News
In brief: ACU-Serve’s executive boost, CMS’s next prior auth move, McKesson’s & Medline’s results - HME News
McKesson Corporation Just Beat EPS By 9.0%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Securian Asset Management Inc. Has $2.75 Million Holdings in McKesson Corporation $MCK - MarketBeat
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $850 to $1,050 - Moomoo
McKesson Earnings Call Highlights Growth, Cash Power - The Globe and Mail
McKesson Corporation (NYSE:MCK) Q4 2026 Earnings Call Transcript - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
McKesson Corporation 2026 Annual Report: Business Segments, Financials, Risk Factors, and Corporate Governance Overview - Minichart
BlackRock Large Cap Focus Growth Fund, Inc.'s McKesson Corp(MCK) Holding History - GuruFocus
MCK Maintained by JP Morgan -- Price Target Lowered to $1015 - GuruFocus
McKesson Corp. stock underperforms Friday when compared to competitors - MarketWatch
McKesson (MCK) Q4 2026 Earnings Transcript - The Globe and Mail
MCK Maintained by Evercore ISI Group -- Price Target Lowered to $850 - GuruFocus
MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up - Zacks Investment Research
Raub Brock Capital Management LP's McKesson Corp(MCK) Holding History - GuruFocus
McKesson: Fiscal Q4 Earnings Snapshot - theheraldreview.com
Does McKesson's (MCK) Bigger Credit Line Quietly Redefine Its Capital Allocation Priorities? - Yahoo Finance
McKesson Q4 FY2026 slides: EPS beats amid revenue shortfall - Investing.com
Earnings call transcript: McKesson Q4 2026 beats EPS but misses revenue - Investing.com
Compared to Estimates, McKesson (MCK) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
McKesson (NYSE: MCK) plans Medical-Surgical spin with $1.25B Apollo stake - Stock Titan
McKesson Corp (NYSE:MCK) Q4 Earnings: Revenue Miss Weighs on Stock After Hours - ChartMill
McKesson (NYSE:MCK) Misses Q1 CY2026 Revenue Estimates - Barchart.com
McKesson posts Q1 earnings beat, but revenue misses estimates; Shares fall 2% - Investing.com
Q4 2026 McKesson Corp Earnings Call Transcript - GuruFocus
McKesson Corp (MCK) Earnings: Q4 Adjusted EPS Surpasses Expectations Amid Revenue Trends - Smartkarma
McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets - ChartMill
McKesson (NYSE: MCK) grows revenue 12%, boosts $7.7B buyback plan - Stock Titan
McKesson earnings loom as GLP-1 script shifts test margins - Investing.com
Brian Madden’s Top Picks for May 7, 2026 - BNN Bloomberg
Should You Buy, Sell, or Hold McKesson Before Q4 Earnings? - Eastern Progress
Brian Madden's Top Picks: Agnico Eagle, McKesson Corp & Costco - BNN Bloomberg
Mckesson Corp Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):